The use of monoclonal antibodies and related agents in the treatment of respiratory disease.
Monoclonal antibodies were first developed in 1975. Since their introduction they have had a progressively increasing impact on different areas of medical diagnostics and therapeutics. Currently, many monoclonal antibodies are under investigation for their potential role in pulmonary medicine. This review discusses a brief history of monoclonal antibodies; the manufacture, use, biosafety and nomenclature of these agents; the inflammatory response in asthma; and the use of omalizumab, an FDA-approved monoclonal antibody for use in asthma, will be described in detail, as well as its associated adverse effects. Additionally, other related biologic agents that may have a role in respiratory diseases are presented.
Schachter
E Neil
EN
Division of Pulmonary Medicine, Mount Sinai School of Medicine, New York, USA. neil.schachter@mssm.edu
Neuman
Tzvi
T
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D000069444:Omalizumab; D012140:Respiratory Tract Diseases / Q000188:drug therapy* / Q000276:immunology
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab